2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Anticancer Res. 2014 Jan;34(1):61-7.
The prognosis for patients with glioblastoma is very poor, despite intensive treatment, including surgery and chemoradiotherapy. Wilms' tumor 1 (WT1) is expressed in most glioblastoma samples, and immunotherapy targeting WT1 has proven to be effective in recurrent glioblastoma. However, the functional roles of WT1 in glioblastoma are not clear. To examine the functional roles of WT1 in glioblastoma, glioblastoma cell lines with reduced WT1 expression were generated using short hairpin RNA(shRNA)-expressing lentivirus. Proliferation of WT1-knockdown glioblastoma cells was significantly slower than control cells with high WT1 expression. In addition, apoptosis was increased in WT1-knockdown glioblastoma cells. Furthermore, WT1-knockdown glioblastoma cells, and control glioblastoma cells were intra-cranially injected into immunodeficient mice. In vivo tumor growth of WT1-knockdown glioblastoma cells was significantly reduced compared to control glioblastoma cells. These results show that WT1 is involved in glioblastoma cell proliferation and apoptosis and that this protein has oncogenic roles in glioblastoma.
尽管进行了包括手术和放化疗在内的强化治疗,胶质母细胞瘤患者的预后仍然非常差。Wilms 瘤 1(WT1)在大多数胶质母细胞瘤样本中表达,针对 WT1 的免疫疗法已被证明对复发性胶质母细胞瘤有效。然而,WT1 在胶质母细胞瘤中的功能作用尚不清楚。为了研究 WT1 在胶质母细胞瘤中的功能作用,使用表达短发夹 RNA(shRNA)的慢病毒生成 WT1 表达降低的胶质母细胞瘤细胞系。与高 WT1 表达的对照细胞相比,WT1 敲低的胶质母细胞瘤细胞的增殖明显减慢。此外,WT1 敲低的胶质母细胞瘤细胞中的细胞凋亡增加。此外,将 WT1 敲低的胶质母细胞瘤细胞和对照胶质母细胞瘤细胞颅内注射到免疫缺陷小鼠中。与对照胶质母细胞瘤细胞相比,WT1 敲低的胶质母细胞瘤细胞的体内肿瘤生长明显减少。这些结果表明 WT1 参与胶质母细胞瘤细胞的增殖和凋亡,并且该蛋白在胶质母细胞瘤中具有致癌作用。